Peptide Liraglutide 99% Purity

Liraglutide Peptide

Polypeptide

GLP-1 receptor agonist (acylated GLP-1 analog, 31-amino-acid peptide)

FDA-approved (Victoza 2010, Saxenda 2014 for obesity)

A 31-amino-acid GLP-1 analog with a C16 fatty-acid chain (palmitoyl) attached to Lys26 via a gamma-glutamic acid spacer. This fatty-acid modification enables reversible binding to serum albumin, extending the half-life to ~13 hours. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.

~10 nM

DrugBank: DB06655; Knudsen LB, et al. J Med Chem. 2000;43(9):1664-1669.DOI

NCT00781922; NCT01272219

Victoza, Saxenda (approved 2010-01-25)

CHEMBL1213363

DB06655

D09199

PubChem

FDA: Victoza (NDA 022341); NEJM: Marso et al. (2016) — LEADER CV outcomes

Liraglutide is FDA-approved as a prescription medicine (Victoza for T2DM, Saxenda for obesity). This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.